Key Takeaways
- Palestinian and Jordanian ministries condemned US Ambassador Mike Huckabee for claiming Israel has a "biblical right" to control the Middle East from the Nile to the Euphrates.
- Johnson & Johnson (JNJ) announced landmark data showing 80.8% of ulcerative colitis patients achieved clinical remission after 140 weeks of Tremfya treatment.
- President Zelenskyy and NATO’s Mark Rutte coordinated on the PURL initiative, focusing on energy security and the upcoming trilateral peace format.
- Renewed clashes in the West Bank town of Beita underscore rising regional instability following the Ambassador's provocative statements.
The Palestinian Foreign Ministry has issued a blistering condemnation of statements made by the U.S. Ambassador to Israel, Mike Huckabee. In a recent interview, Huckabee asserted that Israel possesses a "Torah right" to control the entire Middle East, spanning from the Nile to the Euphrates. The Ministry called the remarks a "direct call to violate state sovereignty" and noted they completely contradict the official position of the U.S. President, who has previously rejected the annexation of the West Bank.
Jordan’s Foreign Ministry joined the condemnation, labeling the Ambassador's comments as "reckless and provocative." Regional diplomats are now calling on the U.S. Administration to take a clear and explicit stance to mitigate the fallout. These developments come as geopolitical analysts warn that such rhetoric could undermine ongoing efforts toward a lasting peace vision and fuel further unrest in the occupied territories.
In the healthcare sector, Johnson & Johnson (JNJ) reported significant long-term results from its QUASAR long-term extension study. The data revealed that Tremfya (guselkumab) sustained clinical and endoscopic remission in adults with moderately to severely active ulcerative colitis (UC) through three years (140 weeks). Notably, 78.6% of patients achieved histo-endoscopic mucosal improvement, a key indicator of deep intestinal healing.
The QUASAR results, presented at the European Crohn's and Colitis Organisation (ECCO) 2026 conference, bolster J&J’s position in the competitive immunology market. Investors are closely watching Tremfya's performance as it remains the first FDA-approved dual-acting monoclonal antibody to block IL-23. The study also confirmed that efficacy was maintained regardless of prior treatment history, including patients who previously failed on other biologics or JAK inhibitors.
On the diplomatic front, Ukrainian President Volodymyr Zelenskyy held a high-level meeting with NATO Secretary General Mark Rutte. The discussions focused on the Prioritised Ukraine Requirements List (PURL), an initiative that has supplied approximately 75% of Ukraine's Patriot missiles since last summer. Zelenskyy also updated Rutte on preparations for the next trilateral format meeting, as the war enters its fifth year amid tense negotiations in Geneva.
The leaders emphasized the critical need to protect civilian energy infrastructure following a record wave of Russian ballistic missile strikes. Rutte reaffirmed that NATO "stands with Ukraine in word and in deed," highlighting direct investments in Ukraine’s defense industry. The coordination between Kyiv and NATO remains a cornerstone of European security as the June deadline for a potential peace agreement approaches.
Meanwhile, local tensions remain high as clashes erupted between Palestinian youths and Israeli forces in the town of Beita, south of Nablus. The confrontation followed a storming of the town by occupation forces, involving the use of live ammunition and tear gas. These incidents highlight the volatile security environment in the West Bank, which continues to be exacerbated by expansionist rhetoric and settler activity.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.